The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease
The Timed Up and Go (TUG) test has been used to assess balance and mobility in Parkinson's Disease (PD). However, it is not known if this test is sensitive to subtle abnormalities present in early stages of the disease, when balance and gait problems are not clinically evident but may be detect...
Saved in:
Published in | Journal of neurology, neurosurgery and psychiatry Vol. 81; no. 2; pp. 171 - 176 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group Ltd
01.02.2010
BMJ Publishing Group BMJ Publishing Group LTD |
Subjects | |
Online Access | Get full text |
ISSN | 0022-3050 1468-330X 1468-330X |
DOI | 10.1136/jnnp.2009.173740 |
Cover
Loading…
Summary: | The Timed Up and Go (TUG) test has been used to assess balance and mobility in Parkinson's Disease (PD). However, it is not known if this test is sensitive to subtle abnormalities present in early stages of the disease, when balance and gait problems are not clinically evident but may be detected with instrumented analysis of movement. We hypothesise that postural transitions and arm swing during gait will be the most sensitive characteristics of the TUG for early PD. In the present study, we instrumented the TUG test (iTUG) using portable inertial sensors, and extended the walking distance from 3 m (traditional TUG) to 7 m. Twelve subjects with early-to-moderate, untreated PD and 12 healthy individuals participated. Our findings show that although the stopwatch measure of TUG duration did not detect any abnormalities in early-to-mid-stage PD, the peak arm swing velocity on the more affected side, average turning velocity, cadence and peak trunk rotation velocity were significantly slower. These iTUG parameters were also correlated with the Unified Parkinson's Disease Rating Motor Scale. Thus, the iTUG test is sensitive to untreated PD and could potentially detect progression of PD and response to symptomatic and disease-modifying treatments. |
---|---|
Bibliography: | ArticleID:jnnp173740 href:jnnp-81-171.pdf local:jnnp;81/2/171 PMID:19726406 ark:/67375/NVC-B3ZJPKS7-J istex:8F743F97DD5EA1888083EF12EF0208D4F7B3EFC2 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0022-3050 1468-330X 1468-330X |
DOI: | 10.1136/jnnp.2009.173740 |